Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Khan

Showing results (341-350 of 366) with videos related to

Pageof 37
Sort By:
Nucleic Acids Research|November 14, 2023
JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profilesIeva Rauluseviciute, Rafael Riudavets-Puig, Romain Blanc-Mathieu, et al.
Nucleic Acids Research|November 9, 2019
JASPAR 2020: update of the open-access database of transcription factor binding profilesOriol Fornes, Jaime A Castro-Mondragon, Aziz Khan, et al.
Scientific Reports|April 15, 2016
Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell lineAmit Kumar, Wasim Abbas, Laurence Colin, et al.
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Nucleic Acids Research|December 1, 2021
JASPAR 2022: the 9th release of the open-access database of transcription factor binding profilesJaime A Castro-Mondragon, Rafael Riudavets-Puig, Ieva Rauluseviciute, et al.
Plos One|February 9, 2017
Comparative study of extrapolative factors linked with oxidative injury and anti-inflammatory status in chronic kidney disease patients experiencing cardiovascular distressMahmood Rasool, Muhammad Abdul Basit Ashraf, Arif Malik, et al.
JAMA Oncology|April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical TrialKevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Cardiology and Therapy|November 6, 2024
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in IndiaUday M Jadhav, Saumitra Ray, T Govindan Unni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.
Journal of Clinical Lipidology|May 4, 2022
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of IndiaRaman Puri, Vimal Mehta, P Barton Duell, et al.
Pageof 37

Showing results (341-350 of 366) with videos related to

Sort By:
Pageof 37
Nucleic Acids Research|November 14, 2023
JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profilesIeva Rauluseviciute, Rafael Riudavets-Puig, Romain Blanc-Mathieu, et al.
Nucleic Acids Research|November 9, 2019
JASPAR 2020: update of the open-access database of transcription factor binding profilesOriol Fornes, Jaime A Castro-Mondragon, Aziz Khan, et al.
Scientific Reports|April 15, 2016
Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell lineAmit Kumar, Wasim Abbas, Laurence Colin, et al.
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Nucleic Acids Research|December 1, 2021
JASPAR 2022: the 9th release of the open-access database of transcription factor binding profilesJaime A Castro-Mondragon, Rafael Riudavets-Puig, Ieva Rauluseviciute, et al.
Plos One|February 9, 2017
Comparative study of extrapolative factors linked with oxidative injury and anti-inflammatory status in chronic kidney disease patients experiencing cardiovascular distressMahmood Rasool, Muhammad Abdul Basit Ashraf, Arif Malik, et al.
JAMA Oncology|April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical TrialKevin J Harrington, Robert L Ferris, Maura Gillison, et al.
Cardiology and Therapy|November 6, 2024
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in IndiaUday M Jadhav, Saumitra Ray, T Govindan Unni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.
Journal of Clinical Lipidology|May 4, 2022
Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of IndiaRaman Puri, Vimal Mehta, P Barton Duell, et al.
Pageof 37